Produtos à base de Cannabis Sativa para uso veterinário: usos, regulamentação, desafios e perspectivas

Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs. 1981; 13: 23–34. Disponível em: [https://doi.org/10.1080/02791072.1981.10471447]. Zuardi AW. History of Cannabis as a medicine: a review. Braz J Psychiatry. 2006; 28: 153–7. Disponível em: [https://doi.org/10.1590/S1516-44462006000200015]. De Briyne N, Holmes D, Sandler I, Stiles E, Szymanski D, Moody S, et al. Cannabis, cannabidiol oils and tetrahydrocannabinol—what do veterinarians need to know? Animals. 2021; 11: 1–19. Disponível em: [https://doi.org/10.3390/ani11030892]. Pierro Neto PA, Pierro LMC, Fernandes ST. Cannabis: 12.000 anos de experiências e preconceitos. Brazil J Pain. 2023; 6: 80-4. Disponível em: [https://doi.org/10.5935/2595-0118.20230055-PT]. Hazzah T, Andre C, Richter G, McGrath S. Cannabis in Veterinary Medicine A Critical Review. AHVMA J. 2020; 61: 17-41. Disponível em: [https://www.ahvma.org/wp-content/uploads/Cannabis-in-Veterinary-Medicine-A-Critical-Review-Vol-61_LR-3.pdf]. Brutlag A, Hommerding H. Toxicology of Marijuana, Synthetic Cannabinoids, and Cannabidiol in Dogs and Cats. Vet Clin North Am Small Anim Pract. 2018; 48: 1087–102. Disponível em: [https://doi.org/10.1016/J.CVSM.2018.07.008]. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of Cannabis and cannabinoids. Anaesthesia. 2001; 56: 1059–68. [https://doi.org/10.1111/j.1365-2044.2001.02269.x]. Hartmann A, Lisboa SF, Sonego AB, Coutinho D, Gomes FV, Guimarães FS. Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 94. Disponível em: [https://doi.org/10.1016/J.PNPBP.2019.109637]. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Ver. 2006; 58: 389–462. Disponível em: [https://doi.org/10.1124/PR.58.3.2]. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998; 359: 1–18. Disponível em: [https://doi.org/10.1016/S0014-2999(98)00649-9]. Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, et al. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018; 227: 300–15. Disponível em: [https://doi.org/10.1016/J.JEP.2018.09.004]. Harvey DJ, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav. 1991; 40: 523–32. Disponível em: [https://doi.org/10.1016/0091-3057(91)90358-9]. Silver RJ. The endocannabinoid system of animals. Animals. 2019; 9. Disponível em: [https://doi.org/10.3390/ANI9090686]. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990; 87: 1932–6. Disponível em: [https://doi.org/10.1073/PNAS.87.5.1932]. Bonfá L, Vinagre RCDO, De Figueiredo NV. Uso de canabinóides na dor crônica e em cuidados paliativos. Rev Bras Anestesiol. 2008; 58: 267–79. Disponível em: [https://doi.org/10.1590/S0034-70942008000300010]. Janczyk P, Donaldson CW, Gwaltney S. Two Hundred and Thirteen Cases of Marijuana Toxicoses in Dogs. Vet Hum Toxicol. 2004; 46(1): 19–21. Disponível em: [https://pubmed.ncbi.nlm.nih.gov/14748410/]. Sixpence P, O'Shaughnessy WB, Army B. On the preparations of the indian hemp, or gunjah: Cannabis indica their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Prov Med J Retrosp Med Sci. 1843 Feb 4; 5 (123): 123): 363–369. PMCID: PMC2490264. Disponível em: [https://pmc.ncbi.nlm.nih.gov/articles/PMC2490264/]. Valastro C, Campanile D, Marinaro M, Franchini D, Piscitelli F, Verde R, et al. Characterization of endocannabinoids and related acylethanolamides in the synovial fluid of dogs with osteoarthritis: a pilot study. BMC Vet Res. 2017; 13. Disponível em: [https://doi.org/10.1186/S12917-017-1245-7]. Brioschi FA, Di Cesare F, Gioeni D, Rabbogliatti V, Ferrari F, D’urso ES, et al. Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis. Anim Open Access J MDPI. 2020; 10: 1–14. Disponível em: [https://doi.org/10.3390/ANI10091505]. Potschka H, Bhatti SFM, Tipold A, McGrath S. Cannabidiol in canine epilepsy. Vet J. 2022; 290: 105913. Disponível em: [https://doi.org/10.1016/j.tvjl.2022.105913]. Vaughn DM, Paulionis LJ, Kulpa JE. Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs. Am J Vet Res. 2021; 82: 405–16. Disponível em: [https://doi.org/10.2460/AJVR.82.5.405]. Cunha RZ, Felisardo LL, Salamanca G, Marchioni GG, Neto OI, Chiocchetti R. The use of cannabidiol as a novel treatment for oral stereotypic behaviour (crib-biting) in a horse. Vet Anim Sci. 2023; 19: 100289. Disponível em: [https://doi.org/10.1016/J.VAS.2023.100289]. Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, et al. Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Front Vet Sci. 2018; 5: 1–9. Disponível em: [https://doi.org/10.3389/fvets.2018.00165]. Repetti CSF, Girio RJS, Friolani M, Barbalho SM. Perspectives in veterinary medicine on the use of cannabinoids as complementary palliative therapy for pain in cancer patients. Ciênc Rural. 2019; 49(2) :1-7. Disponível em: [https://doi.org/10.1590/0103-8478CR20180595]. Brasil. Ministério da Agricultura e Pecuária (MAPA). Instrução Normativa no 11, de 8 de junho de 2005. Estabelece as normas para a manipulação de produtos veterinários. Diário Oficial da União, Brasília, DF, 8 jun. 2005. Zgair A, Lee JB, Wong JCM, Taha DA, Aram J, Di Virgilio D, et al. Oral administration of Cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep. 2017; 7: 14542. Disponível em: [https://doi.org/10.1038/S41598-017-15026-Z]. Bartner LR, Mcgrath S, Rao S, Hyatt LK, Wittenburg LA. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Can J Vet Res. 2018: 178–83. Disponível em: [https://doi.org/10.1136/cjvr.2018]. Vaughn D, Kulpa J, Paulionis L. Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs. Front Vet Sci. 2020; 7: 508350. Disponível em: [https://doi.org/10.3389/fvets.2020.00051]. McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. 2019; 254: 1301–8. Disponível em: [https://doi.org/10.2460/JAVMA.254.11.1301]. Kogan L, Schoenfeld-Tacher R, Hellyer P, Rishniw M. US Veterinarians’ Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions. Front Vet Sci. 2019; 5. Disponível em: [https://doi.org/10.3389/FVETS.2018.00338]. Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. Animals. 2019; 9(10): 832. Disponível em: [https://doi.org/10.3390/ANI9100832]. Ellis KL, Contino EK. Treatment using cannabidiol in a horse with mechanical allodynia. Equine Vet Educ. 2021; 33: e79–82. Disponível em: [https://doi.org/10.1111/EVE.13168]. De Álava AF. Cannabis de uso medicinal para el tratamiento de dolor crónico de un labrador retriever con osteoartrosis: relato del caso. Montevideo, 2019. Tese de Doutorado [Programa de pós-graduação em Ciência Veterinárias] Universidad de la Republica. Fernández-trapero M, Pérez-díaz C, Espejo-porras F, de Lago E, Fernández-ruiz J. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. Biomolecules. 2020; 10. Disponível em: [https://doi.org/10.3390/biom10020279]. Łebkowska-Wieruszewska B, Stefanelli F, Chericoni S, Owen H, Poapolathep A, Lisowski A, et al. Pharmacokinetics of Bedrocan®, a Cannabis oil extract, in fasting and fed dogs: An explorative study. Res Vet Sci. 2019; 123: 26–8. Disponível em: [https://doi.org/10.1016/J.RVSC.2018.12.003]. Meola SD, Tearney CC, Haas SA, Hackett TB, Mazzaferro EM. Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010). J Vet Emerg Crit Care. 2012; 22: 690–6. Disponível em: [https://doi.org/10.1111/J.1476-4431.2012.00818.X]. Miranda ALS de, Soto-Blanco B, Melo MM. Intoxicações de cães por drogas recreativas: maconha e cocaína. Rev Cient Eletr Med Vet. 2017; 1–8. [https://pesquisa.bvsalud.org/portal/resource/pt/vti-690817]. Weller JE, Flint HE, Hunt ABG, Ellerby Z, King T. Investigating the effect a single dose of cannabidiol has on measures of stress in cats when being transported in a carrier and meeting a novel person in an unfamiliar environment. Front Vet Sci. 2024; 11: 1476296. Disponível em: [https://doi.org/10.3389/fvets.2024.1476296]. Kulpa JM, Paulionis L, Zawislak C, Lamy E. Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs. Front Vet Sci. 2023; 10: 1324622. Disponível em: [https://doi.org/10.3389/fvets.2023.1324622]. Hazzah T. The Use of Medical Cannabis as Palliative Care in a Feline with Advanced Cancer. J Am Holist Vet Med Assoc. 2024; 74: 26–34. Disponível em: [https://doi.org/10.56641/OXLY5458]. De pets até pinguins: produtos à base de Cannabis ganham espaço na medicina veterinária no interior de SP | Tem mais pet | G1. 2024 set. 26. [acesso em: 18 fev 2025]. Disponível em: [https://g1.globo.com/sp/sorocaba-jundiai/tem-mais-pet/noticia/2024/09/26/de-pets-ate-pinguins-produtos-a-base-de-Cannabis-ganham-espaco-na-medicina-veterinaria-no-interior-de-sp.ghtml]. McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. 2019; 254: 1301–8. Disponível em: [https://doi.org/10.2460/JAVMA.254.11.1301]. Binagia EM, Gregory EA, Yankin I. Clinical examination findings and electrolyte abnormalities of dogs with marijuana/tetrahydrocannabinol toxicity: 223 cases (January 2017–July 2021). J Am Vet Med Assoc. 2024; 262: 1047–54. Disponível em: [https://doi.org/10.2460/JAVMA.24.02.0092]. Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol. 1973; 25: 363–72. Disponível em: [https://doi.org/10.1016/0041-008X(73)90310-4]. Kulpa JE, Paulionis LJ, Eglit GML, Vaughn DM. Safety and tolerability of escalating cannabinoid doses in healthy cats. J Feline Med Surg. 2021; 23:1162. Disponível em: [https://doi.org/10.1177/1098612X211004215]. Wakshlag JJ, Cital S, Eaton SJ, Prussin R, Hudalla C. Cannabinoid, Terpene, and Heavy Metal Analysis of 29 Over-the-Counter Commercial Veterinary Hemp Supplements. Vet Med Res Rep. 2020; 11: 45–55. Disponível em: [https://doi.org/10.2147/vmrr.s248712]. Russo EB. The case for the entourage effect and conventional breeding of clinical Cannabis: No “Strain,” no gain. Front Plant Sci. 2019; 9: 434025. Disponível em: [https://doi.org/10.3389/fpls.2018.01969]. Russo EB, Marcu J. Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Adv Pharmacol 2017; 80: 67–134. Disponível em: [https://doi.org/10.1016/BS.APHA.2017.03.004]. Good Manufacturing Practices (GMP). Guidelines for Cannabis Quality Control in Veterinary Medicine. Good Manufacturing Practices Report. 2021. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). Produtos à base de Cannabis poderão ser regularizados para uso em animais. 2024. [acesso em: 10 fev 2025]. Disponível em: [https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/produtos-a-base-de-Cannabis-poderao-ser-regularizados-para-uso-em-animais] Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). Resolução da Diretoria Colegiada - RDC nº 327, de 09 de dezembro de 2019. Resolução da Diretoria Colegiada - RDC nº 327, de 09 de dezembro de 2019. Diário Oficial da União, Brasília, DF, 9 dez. 2019; p. 1–30. [https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2019/rdc0327_09_12_2019.pdf]. Conselho Federal de Medicina Veterinária (CFMV). Uso da Cannabis na Medicina Veterinária é aprovado pela Anvisa. Disponível em: [https://www.cfmv.gov.br/uso-da-Cannabis-na-medicina-veterinaria-e-aprovado-pela-anvisa/comunicacao/noticias/2024/10/30/].